Effects of methylprednisolone and cyclosporine A on fungal growth in vitro

Cornea

Volumn 18, Issue 3, 1999, Pages 306-313

  Bell, Nicholas P ^a   Karp, Carol L ^a   Alfonso, Eduardo C ^a   Schiffman, Joyce ^a   Miller, Darlene ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroids; Cyclosporine A; Fungal keratitis; Keratoplasty

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DOSE RESPONSE; FUNGUS GROWTH; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; KERATITIS; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNGI; GLUCOCORTICOIDS; METHYLPREDNISOLONE;

EID: 0032912261     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-199905000-00012     Document Type: Article

References (26)

1. O'Day DM. Corticosteroids: an unresolved debate. Ophthalmology 1991;98:845-6.
2. O'Day DM, Ray WA, Head WS, Robinson RD, Williams TE. Influence of corticosteroid on experimentally induced keratomycosis. Arch Ophthalmol 1991;109:1601-4.
3. Stern GA, Buttross M. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology 1991;98:847-53.
4. Hill JC. Immunosuppression in corneal transplantation. Eye 1995; 9:247-53.
5. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea 1990;9:184-95.
6. Olsen TW, Gothard TW, Holland EJ. Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model. Cornea 1996;15:76-81.
7. Benelli U, Ross JR, Nardi M, Klintworth GK. Corneal neovascularization induced by xenografts or chemical cautery: inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 1997;38:274-82.
8. Salisbury MA, Kaswan RL, Brown J. Microorganisms isolated from the corneal surface before and during cyclosporine treatment in dogs with keratoconjunctivitis sicca. Am J Veterinary Res 1995; 56:880-4.
9. Stähelin HF. The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia 1996;52:5-13.
10. Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6:468-75.
11. Kanpolat A, Batioglu F, Yilmaz M, Akbas F. Penetration of cyclosporin A into the rabbit cornea and aqueous humor after topical drop and collagen shield administration. CLAO J 1994;20:119-22.
12. Mosteller MW, Gebhardt BM, Hamilton AM, Kaufman HE. Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum. Arch Ophthalmol 1985;103:101-2.
13. Cheeks L, Kaswan RL, Green K. Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea. Curr Eye Res 1992;11:641-9.
14. Vecchiarelli A, Cenci E, Marconi P, Rossi R, Riccardi C, Bistoni F. Immunosuppressive effect on cyclosporin A on resistance to systemic infection with Candida albicans. J Med Microbiol 1989; 30:183-92.
15. Roilides E, Robinson T, Sein T, Pizzo PA, Walsh TJ. In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus. Antimicrob Agents Chemother 1994;38:2883-8.
16. Goichot-Bonnat L, DeBeauregard C, Saragoussi JJ, Pouliquen Y. Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results. J Fr Ophtalmol 1987; 10:213-7.
17. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96: 1144-50.
18. Archeampong A, Shackleton M, Lam S, Rudewicz P, Tang-Liu D. Cyclosporine distribution into the conjunctiva, corneal, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog and human eyes. In: Sullivan, et al. Lacrimal gland, tear film, and dry eye syndromes 2: basic science and clinical review. New York: Plenum Press, 1998:1001-4.
19. Nussenblatt R. The expanding use of immunosuppression in the treatment of non-infectious ocular disease. J Autoimmunity 1992; 5(suppl A):247-57.
20. Towler HMA, Lightman SL, Forrester JV. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmunity 1992;5(suppl A):259-64.
21. Solch S, Nadler PI, Silverman MH. Phase I safety and tolerability studies of 2% cyclosporin (Cy) (Sandimmune) ophthalmic ointment. J Autoimmunity 1992;5(suppl A):Abstract 123.
22. Kanal A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc 1989;21:3150-2.
23. Apel A, Oh C, Chiu R, Saville B, Cheng Y, Rootman D. A sub-conjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Curr Eye Res 1995;14:659-67.
24. Chen YF, Gebhardt BM, Reidy JJ, Kaufman HE. Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 1990;109:132-7.
25. Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye. Cornea 1990;9: 196-9.
26. Gebhardt B, Kaufman H. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocular Pharmacol 1995;11:319-27.